Not finding it? Sign in to also search OpenAlex live.
-
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Andrew Tucker Kuykendall, Aniket Bankar, Kristen Marie Pettit, Joseph James Shatzel, Alessandro Lucchesi, Valentín García‐Gutiérrez, +20 more
3citations -
Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)
Jeanette Walter, Benjamin Rolles, Frauke Theis, Leo Hansmann, Daniel Heudobler, Markus Philipp Radsak, +10 more
0citations -
Modeling the Polarization-Dependent Microstructure-Resolved Distribution of Oxygen Chemical Potential in Ceria-Based Electrolysis Cells2025 ECS Meeting Abstracts conference-abstract Materials Science Advancements in Solid Oxide Fuel Cells
Iurii Kogut, Christian Lenser, Denise Ramler, Stefan Kucharski, Luzie Wehner, E. Wessel, +2 more
0citations -
POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Philip J. Mease, A.B. Gottlieb, Iain B. McInnes, Proton Rahman, Alexa P. Kollmeier, X. L. Xu, +6 more
1citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Marc Steffen Raab, Niels Weinhold, Klaus Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, +23 more
47citations -
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.2024 Journal of Clinical Oncology conference-abstract Medicine Lymphoma Diagnosis and Treatment Open access
Leslie A. Lori, Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, David Belada, Marcel Nijland, +8 more
9citations -
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Letícia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, +8 more
5citations -
OP0324 LONG-TERM SUSTAINABILITY OF METHOTREXATE INTERVENTION IN ANTICITRULLINATED PROTEIN ANTIBODY-POSITIVE AND AUTOANTIBODY-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RHEUMATOID ARTHRITIS ON DISEASE DEVELOPMENT AND DISEASE BURDEN; 5 YEAR RESULTS FROM THE TREAT EARLIER TRIAL2025 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
Quirine A Dumoulin, Hanna W. van Steenbergen, Doortje I Krijbolder, W. Edward Visser, S. Böhringer, Annette H M van der Helm–van Mil
4citations -
Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Marie José Kersten, Kirsten Saevels, Évelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, +9 more
3citations -
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Marie José Kersten, Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Maria Theresa Kuipers, Évelyne Willems, Sébastien Anguille, +14 more
3citations -
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Lori Ann Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Haaber Christensen, Alexander Fosså, +8 more
2citations -
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.2025 Journal of Clinical Oncology conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kristen Marie Pettit, Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, +14 more
0citations